Literature DB >> 28943075

A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer.

Avani D Rao1, Ziwei Feng1, Eun Ji Shin2, Jin He3, Kevin M Waters4, Stephanie Coquia5, Robert DeJong5, Lauren M Rosati1, Lin Su1, Dengwang Li1, Juan Jackson1, Stephen Clark1, Jeffrey Schultz1, Danielle Hutchings4, Seong-Hun Kim2, Ralph H Hruban4, Theodore L DeWeese1, John Wong1, Amol Narang1, Joseph M Herman1, Kai Ding6.   

Abstract

PURPOSE: We assessed the feasibility and theoretical dosimetric advantages of an injectable hydrogel to increase the space between the head of the pancreas (HOP) and duodenum in a human cadaveric model. METHODS AND MATERIALS: Using 3 human cadaveric specimens, an absorbable radiopaque hydrogel was injected between the HOP and duodenum by way of open laparotomy in 1 case and endoscopic ultrasound (EUS) guidance in 2 cases. The cadavers were subsequently imaged using computed tomography and dissected for histologic confirmation of hydrogel placement. The duodenal dose reduction and planning target volume (PTV) coverage were characterized using pre- and postspacer injection stereotactic body radiation therapy (SBRT) plans for the 2 cadavers with EUS-guided placement, the delivery method that appeared the most clinically desirable. Modeling studies were performed using 60 SBRT plans consisting of 10 previously treated patients with unresectable pancreatic cancer, each with 6 different HOP-duodenum separation distances. The duodenal volume receiving 15 Gy (V15), 20 Gy (V20), and 33 Gy (V33) was assessed for each iteration.
RESULTS: In the 3 cadaveric studies, an average of 0.9 cm, 1.1 cm, and 0.9 cm HOP-duodenum separation was achieved. In the 2 EUS cases, the V20 decreased from 3.86 cm3 to 0.36 cm3 and 3.75 cm3 to 1.08 cm3 (treatment constraint <3 cm3), and the V15 decreased from 7.07 cm3 to 2.02 cm3 and 9.12 cm3 to 3.91 cm3 (treatment constraint <9 cm3). The PTV coverage improved or was comparable between the pre- and postinjection studies. Modeling studies demonstrated that a separation of 8 mm was sufficient to consistently reduce the V15, V20, and V33 to acceptable clinical constraints.
CONCLUSIONS: Currently, dose escalation has been limited owing to radiosensitive structures adjacent to the pancreas. We demonstrated the feasibility of hydrogel separation of the HOP and duodenum. Future studies will evaluate the safety and efficacy of this technique with the potential for more effective dose escalation using SBRT or intensity-modulated radiation therapy to improve the outcomes in patients with unresectable pancreatic cancer.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28943075      PMCID: PMC5699940          DOI: 10.1016/j.ijrobp.2017.08.006

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Novel use of a hydrogel spacer permits reirradiation in otherwise incurable recurrent gynecologic cancers.

Authors:  Akila N Viswanathan; Antonio L Damato; Paul L Nguyen
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

2.  Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer.

Authors:  Michael Pinkawa; Vanessa Berneking; Liane König; Dilini Frank; Marilou Bretgeld; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2016-09-08       Impact factor: 3.621

3.  A radiopaque polymer hydrogel used as a fiducial marker in gynecologic-cancer patients receiving brachytherapy.

Authors:  Ryan J Bair; Eric Bair; Akila N Viswanathan
Journal:  Brachytherapy       Date:  2015-10-23       Impact factor: 2.362

4.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

5.  Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy.

Authors:  Gencay Hatiboglu; Michael Pinkawa; Jean-Paul Vallée; Boris Hadaschik; Markus Hohenfellner
Journal:  BJU Int       Date:  2012-07-12       Impact factor: 5.588

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

8.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors.

Authors:  H N Ismael; J Denbo; S Cox; C H Crane; P Das; S Krishnan; R T Schroff; M Javle; C Conrad; J Vauthey; T Aloia
Journal:  Eur J Surg Oncol       Date:  2016-06-02       Impact factor: 4.424

10.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

View more
  23 in total

Review 1.  The role of radioprotective spacers in clinical practice: a review.

Authors:  Qiuying Tang; Feng Zhao; Xiaokai Yu; Lingyun Wu; Zhongjie Lu; Senxiang Yan
Journal:  Quant Imaging Med Surg       Date:  2018-06

2.  Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors.

Authors:  Tossapol Kerdsirichairat; Amol K Narang; Elizabeth Thompson; Seong-Hun Kim; Avani Rao; Kai Ding; Eun Ji Shin
Journal:  Gastroenterology       Date:  2019-07-12       Impact factor: 22.682

3.  Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.

Authors:  Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2022-03-17

4.  Dose Prediction Model for Duodenum Sparing With a Biodegradable Hydrogel Spacer for Pancreatic Cancer Radiation Therapy.

Authors:  Ziwei Feng; Avani D Rao; Zhi Cheng; Eun Ji Shin; Joseph Moore; Lin Su; Seong-Hun Kim; John Wong; Amol Narang; Joseph M Herman; Todd McNutt; Dengwang Li; Kai Ding
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-07-19       Impact factor: 7.038

5.  Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Avani Dholakia Rao; Eun Ji Shin; Jeffrey Meyer; Elizabeth L Thompson; Wei Fu; Chen Hu; Elliot K Fishman; Matthew Weiss; Christopher Wolfgang; Richard Burkhart; Jin He; Tossapol Kerdsirichairat; Joseph M Herman; Kai Ding; Amol Narang
Journal:  Pract Radiat Oncol       Date:  2020-03-07

6.  Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.

Authors:  Ze-Tian Shen; Han Zhou; Ao-Mei Li; Xiao-Qin Ji; Chang-Chen Jiang; Xi Yuan; Bing Li; Xi-Xu Zhu; Gui-Chun Huang
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-30       Impact factor: 4.553

7.  Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Pancreatic Malignancy.

Authors:  Seong-Hun Kim; Eun Ji Shin
Journal:  Clin Endosc       Date:  2021-05-28

8.  Demonstration of Safety and Feasibility of Hydrogel Marking of the Pancreas-Duodenum Interface for Image Guided Radiation Therapy (IGRT) in a Porcine Model: Implications in IGRT for Pancreatic Cancer Patients.

Authors:  Avani D Rao; Eun Ji Shin; Sarah E Beck; Caroline Garrett; Seong-Hun Kim; Nam Ju Lee; Eleni Liapi; John Wong; Joseph Herman; Amol Narang; Kai Ding
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-02       Impact factor: 7.038

9.  Investigating a novel split-filter dual-energy CT technique for improving pancreas tumor visibility for radiation therapy.

Authors:  Lianna D Di Maso; Jessie Huang; Michael F Bassetti; Larry A DeWerd; Jessica R Miller
Journal:  J Appl Clin Med Phys       Date:  2018-08-17       Impact factor: 2.102

10.  Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach.

Authors:  Eugene J Koay; Alexander N Hanania; William A Hall; Cullen M Taniguchi; Neal Rebueno; Sten Myrehaug; Katharine L Aitken; Laura A Dawson; Christopher H Crane; Joseph M Herman; Beth Erickson
Journal:  Pract Radiat Oncol       Date:  2020-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.